Project: A novel targeted treatment against ovarian cancer

Acronym nOVAB (Reference Number: 113292)
Duration 01/10/2019 - 03/10/2022
Project Topic We have discovered a specific epitope of a monoclonal antibody (mAb) that blocks a novel tumour cell-specific target, leading to cell death and reduced tumour growth via a novel cancer pathway. The nOVAB consortium aims to develop a mAb against the novel target into a treatment for solid tumours. Positioning of the mAb ultimately would be applicable in non-responders to immunotherapy. nOVAB’s focus on ovarian cancer is the first of solid tumours given there are few therapies available.
Network Eurostars 2
Call Eurostars Cut–off 11

Project partner

Number Name Role Country
1 Temple Therapeutics Coordinator Netherlands
2 InSphero AG Partner Switzerland
3 Xenopat SL Partner Spain
4 Sahlgrenska Cancer Center at The Sahlgrenska Academy at the University of Gothenburg Partner Sweden